HU Group saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of HU Group‘s patent filings and grants. Buy the databook here.
HU Group has been focused on protecting inventions in European Patent Office(EPO) with four publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where HU Group is filings its patents. Among the top granted patent authorities, HU Group has 100% of its grants in United States(US).
Regeneron Pharmaceuticals and Toray Industries could be the strongest competitors for HU Group
Patents related to rare diseases lead HU Group's portfolio
HU Group has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Ovarian cancer related patents lead HU Group portfolio followed by hepatitis e, and uterine cancer
HU Group has highest number of patents in ovarian cancer followed by hepatitis e, uterine cancer, endometrial cancer.
For comprehensive analysis of HU Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.